S

Suburban Research Associates | Media, PA

Research site
(Unclaimed)
Location
107 Chesley Drive, Unit 4, Media, Pennsylvania, United States of America
Site insights

Top conditions

Depressive Disorder (27 trials)

Depression (27 trials)

Major Depressive Disorder (24 trials)

Syndrome (11 trials)

Fragile X Syndrome (9 trials)

Top treatments

Rapastinel
SPD489
Lurasidone
STX209
BPN14770
Aripiprazole
Ecopipam
Arbaclofen
Pimavanserin
Troriluzole

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

15 of 77
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

This is a 2-part study, with each part having a unique set of objectives for male adolescents aged 9 to < 18 years with fragile X syndrome (FXS). Par...

Enrolling
Fragile X Syndrome
Drug: zatolmilast
Drug: Placebo

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving dep...

Enrolling
Depressive Disorder, Major
Anhedonia
Drug: Aticaprant
Other: Placebo

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Enrolling
Depressive Disorder, Major
Drug: Aticaprant

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) with Fragile X Syndrome

Enrolling
Fragile X Syndrome
Drug: BPN14770/ zatolmilast
Drug: Placebo

The purpose of this study is to evaluate the efficacy of JNJ-55308942 compared to placebo on symptoms of depression in participants with bipolar diso...

Enrolling
Bipolar Disorder
Drug: JNJ-55308942
Drug: Placebo

This is a 2-year, open-label extension (OLE) study for subjects completing one of two double-blind clinical trials with BPN14770, Study BPN14770-CNS-...

Invitation-only
Fragile X Syndrome
Drug: Zatolmilast/ BPN14770

This is a Phase 3, multicenter, 56-week, outpatient, open-label (OL) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in d...

Active, not recruiting
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules

This Phase 3 multicenter study evaluates the maintenance of efficacy, safety and tolerability of ecopipam tablets in children, adolescents and adults...

Enrolling
Tourette Disorder
Drug: Ecopipam Hydrochloride

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compu...

Enrolling
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Enrolling
Treatment Resistant Depression
Drug: Psilocybin

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and ad...

Enrolling
Autism Spectrum Disorder
Drug: ML-004 (IR)/(ER) tablet
Drug: ML-004 Placebo

ZYN002 is a pharmaceutically manufactured Cannabidiol that is developed as a clear gel that can be applied to the skin (called transdermal delivery)....

Invitation-only
Fragile X Syndrome
Drug: ZYN002 - Cannabidiol Transdermal Gel

The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive d...

Active, not recruiting
Obsessive-Compulsive Disorder
Drug: Troriluzole
Drug: Placebo

Trial sponsors

S

Sumitomo Pharma America, Inc. (6 trials)

Allergan logo

Allergan (5 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems